Bayer said it will be
opening its files on glyphosate (Roundup) on Dec. 7.
It appears to be an
attempt to get ahead of the damaging news emerging from trials launched by
people who claim they have been sickened by the weed killer that was discovered
by Monsanto, which is now owned by Bayer.
“Our commitment to transparency remains core to our mission as we move forward as a combined company,” said Liam Condon, a member of the Board of Management of Bayer AG and president of the Crop Science Division.
“We
recognize that people around the world want more information around glyphosate
– and we are eager to offer access to our glyphosate-related safety data on our
dedicated transparency platform.
“This
platform has set new standards of accountability and responsibility in the
sector; we pledge to use it as a springboard to continue to share science-based
information with the public,” he said.
Access to the underlying safety study reports – owned by Bayer and submitted for the review that led to the European substance renewal decision in December – will be enabled next year, the company said.
Access to the underlying safety study reports – owned by Bayer and submitted for the review that led to the European substance renewal decision in December – will be enabled next year, the company said.
